The promulgation of the "Regulations on the Clinical Research and Clinical Translation Application of New Biomedical Technologies" (hereinafter referred to as the "Regulations") constitutes a milestone in the history of regulating new biomedical technologies in China, marking the formal entry of this field into a new stage of rule-of-law characterized by "lenient entry, strict exit, and strong supervision". Based on the author's long-term practice experience in the field of clinical research and clinical transformation of stem cells, this article provides a systematic analysis and deep thinking on the legislative background, core framework, and underlying governance logic of the "Regulations". The article points out that the "lenient entry" established by the "Regulations" is, in essence, a dialectical unity of simplified procedural thresholds and strengthened substantive responsibilities. The "strict exit" emphasized by the "Regulations" builds a solid quality and ethical defense line for clinical translation through a national-level "dual-evaluation" mechanism and whole-cycle dynamic supervision. The "strong supervision" it relies on constructs a whole-process, clear-responsibility chain and deterrent system by granting substantive enforcement powers, establishing graded legal liabilities, and implementing a "dual punishment" system for individuals. Particularly importantly, the "Regulations" thoroughly unblock the medical technology pathway within the "dual-track" system for stem cell therapy, and provide clear guidance for technological innovation and translation through the "three stages, dual reviews, dual evaluations" (i.e., "3+2+2") regulatory framework. However, as a framework legislation, the supporting rules and technical guidelines for key links such as the review mechanism, qualification of assessment bodies, clinical application access standards, and the classification criteria of technologies and products in the "Regulations" still need to be clarified, and its implementation still faces challenges from "text" to "practice". Based on this, from the multiple perspectives of medical institutions, enterprises, and regulatory coordination, this article proposes systematic and actionable implementation suggestions, emphasizing that all parties need to plan ahead, consolidate internal capabilities, and collaborate to build together, in order to translate policy opportunities into clinical value, and jointly promote the standardized, safe, and efficient development of China's new biomedical technology industry.